-
1دورية أكاديمية
المؤلفون: Lorenzo G. D., Zappavigna S., Crocetto F., Giuliano M., Ribera D., Morra R., Scafuri L., Verde A., Bruzzese D., Iaccarino S., Costabile F., Onofrio L., Viggiani M., Palmieri A., De Placido P., Marretta A. L., Pietroluongo E., Luce A., Abate M., Navaeiseddighi Z., Caputo V. F., Celentano G., Longo N., Ferro M., Morelli F., Facchini G., Caraglia M., De Placido S., Buonerba C.
المساهمون: Lorenzo, G. D., Zappavigna, S., Crocetto, F., Giuliano, M., Ribera, D., Morra, R., Scafuri, L., Verde, A., Bruzzese, D., Iaccarino, S., Costabile, F., Onofrio, L., Viggiani, M., Palmieri, A., De Placido, P., Marretta, A. L., Pietroluongo, E., Luce, A., Abate, M., Navaeiseddighi, Z., Caputo, V. F., Celentano, G., Longo, N., Ferro, M., Morelli, F., Facchini, G., Caraglia, M., De Placido, S., Buonerba, C.
مصطلحات موضوعية: Abiraterone, Hormonal therapy, LHRH agonist, Liquid biopsy, MDV3100
الوصف: Introduction. Metastatic castration-resistant prostate cancer (mCRPC) is a deadly disease. Enzalutamide is an oral second-generation anti-androgen that is active in mCRPC. Circulating tumor cells (CTC) count correlates with overall survival (OS) in mCRPC, whereas detection of the androgen-receptor splice variant 7 (AR-V7) in CTC predicts poor response to oral second-generation anti-androgens. Also, loss of PTEN (phosphatase and tensin homolog) in CTC is a biomarker of poor prognosis in mCRPC. Patients and methods. In this translational study, we employed flow cytometry to assess total, PTEN–, and AR-V7+ CTC count per 7.5 mL of whole blood in a prospective cohort of patients with mCRPC receiving enzalutamide. Results. CTCs were assessed in a total of 45 men with mCRPC at baseline and at 12 weeks. Overall, CTC, PTEN– CTC, and AR-V7+ CTC detection rate was high, at baseline, with 84.4%, 71.1%, and 51.1% of samples showing at least 1 cell/7.5-mL blood, respectively, and after 3 months, with 93.3%, 64.4%, and 77.7% of samples showing at least 1 cell/7.5-mL blood, respectively. Median radiographic progression-free survival (rPFS) and OS were 6 (95% confidence interval [CI], 5.6-9) and 14.3 (95% CI, 12.8-20.3) months, respectively. Median (interquartile range) total CTC count at baseline was 5 (3; 8), whereas median (interquartile range) PTEN– CTC count was 2 (0; 4) and median (interquartile range) AR-V7+ CTC count was 1 (0; 3). At baseline, ≥ 5 versus < 5 total CTC count was associated with worse rPFS (hazard ratio [HR], 2.35; 95% CI, 1.14-4.84; P=.021) and OS (HR, 3.08; 95% CI, 1.45-6.54; P =.003), whereas ≥ 2 versus < 2 PTEN– CTC count was associated with worse rPFS (HR, 3.96; 95% CI, 1.8-8.72; P=.001) and OS (HR, 2.36; 95% CI, 1.12-5; P=.025). Finally, ≥ 1 versus < 1 AR-V7+ CTC count was also associated with worse rPFS (HR, 5.05; 95% CI, 2.4-10.64; P<.001) and OS (HR, 2.25; 95% CI, 1.1-4.58; P=.026). Conclusions. Despite multiple limitations, including the small sample size, our preliminary study ...
العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000706855800003; journal:CLINICAL GENITOURINARY CANCER; http://hdl.handle.net/11588/853071Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85105328184; https://www.sciencedirect.com/science/article/pii/S1558767321000847?via=ihubTest
الإتاحة: https://doi.org/10.1016/j.clgc.2021.03.021Test
http://hdl.handle.net/11588/853071Test
https://www.sciencedirect.com/science/article/pii/S1558767321000847?via=ihubTest -
2دورية أكاديمية
المؤلفون: Di Lorenzo G., Zappavigna S., Crocetto F., Giuliano M., Ribera D., Morra R., Scafuri L., Verde A., Bruzzese D., Iaccarino S., Costabile F., Onofrio L., Viggiani M., Palmieri A., De Placido P., Marretta A. L., Pietroluongo E., Luce A., Abate M., Navaeiseddighi Z., Caputo V. F., Celentano G., Longo N., Ferro M., Morelli F., Facchini G., Caraglia M., De Placido S., Buonerba C.
المساهمون: Di Lorenzo, G., Zappavigna, S., Crocetto, F., Giuliano, M., Ribera, D., Morra, R., Scafuri, L., Verde, A., Bruzzese, D., Iaccarino, S., Costabile, F., Onofrio, L., Viggiani, M., Palmieri, A., De Placido, P., Marretta, A. L., Pietroluongo, E., Luce, A., Abate, M., Navaeiseddighi, Z., Caputo, V. F., Celentano, G., Longo, N., Ferro, M., Morelli, F., Facchini, G., Caraglia, M., De Placido, S., Buonerba, C.
مصطلحات موضوعية: Abiraterone, Hormonal therapy, LHRH agonist, Liquid biopsy, MDV3100, Benzamide, Biomarkers, Tumor, Flow Cytometry, Human, Male, Nitrile, PTEN Phosphohydrolase, Phenylthiohydantoin, Prospective Studie, Protein Isoform, Receptors, Androgen, Neoplastic Cells, Circulating, Prostatic Neoplasms, Castration-Resistant
الوصف: Introduction. Metastatic castration-resistant prostate cancer (mCRPC) is a deadly disease. Enzalutamide is an oral second-generation anti-androgen that is active in mCRPC. Circulating tumor cells (CTC) count correlates with overall survival (OS) in mCRPC, whereas detection of the androgen-receptor splice variant 7 (AR-V7) in CTC predicts poor response to oral second-generation anti-androgens. Also, loss of PTEN (phosphatase and tensin homolog) in CTC is a biomarker of poor prognosis in mCRPC. Patients and methods. In this translational study, we employed flow cytometry to assess total, PTEN–, and AR-V7+ CTC count per 7.5 mL of whole blood in a prospective cohort of patients with mCRPC receiving enzalutamide. Results. CTCs were assessed in a total of 45 men with mCRPC at baseline and at 12 weeks. Overall, CTC, PTEN– CTC, and AR-V7+ CTC detection rate was high, at baseline, with 84.4%, 71.1%, and 51.1% of samples showing at least 1 cell/7.5-mL blood, respectively, and after 3 months, with 93.3%, 64.4%, and 77.7% of samples showing at least 1 cell/7.5-mL blood, respectively. Median radiographic progression-free survival (rPFS) and OS were 6 (95% confidence interval [CI], 5.6-9) and 14.3 (95% CI, 12.8-20.3) months, respectively. Median (interquartile range) total CTC count at baseline was 5 (3; 8), whereas median (interquartile range) PTEN– CTC count was 2 (0; 4) and median (interquartile range) AR-V7+ CTC count was 1 (0; 3). At baseline, ≥ 5 versus < 5 total CTC count was associated with worse rPFS (hazard ratio [HR], 2.35; 95% CI, 1.14-4.84; P=.021) and OS (HR, 3.08; 95% CI, 1.45-6.54; P =.003), whereas ≥ 2 versus < 2 PTEN– CTC count was associated with worse rPFS (HR, 3.96; 95% CI, 1.8-8.72; P=.001) and OS (HR, 2.36; 95% CI, 1.12-5; P=.025). Finally, ≥ 1 versus < 1 AR-V7+ CTC count was also associated with worse rPFS (HR, 5.05; 95% CI, 2.4-10.64; P<.001) and OS (HR, 2.25; 95% CI, 1.1-4.58; P=.026). Conclusions. Despite multiple limitations, including the small sample size, our preliminary study ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33958297; info:eu-repo/semantics/altIdentifier/wos/WOS:000706855800003; volume:19; issue:5; firstpage:e286; lastpage:e298; journal:CLINICAL GENITOURINARY CANCER; http://hdl.handle.net/11591/462432Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85105328184
-
3دورية أكاديمية
المؤلفون: Ottaviano M., Curvietto M., Rescigno P., Tortora M., Palmieri G., Giannarelli D., Aieta M., Assalone P., Attademo L., Avallone A., Bloise F., Bosso D., Borzillo V., Buono G., Calderoni G., Caputo F., Carteni G., Cavallero D., Cavo A., Ciardiello F., Conca R., Conteduca V., De Falco S., De Felice M., De Laurentiis M., De Placido P., De Placido S., De Santo I., De Stefano A., Della Corte C. M., Di Franco R., Di Lauro V., Fabbrocini A., Federico P., Festino L., Giordano P., Giuliano M., Gridelli C., Grimaldi A. M., Lia M., Marretta A. L., Massa V., Mennitto A., Merler S., Merz V., Messina C., Messina M., Milano M., Minisini A. M., Montesarchio V., Morabito A., Morgillo F., Mucci B., Nappi L., Napolitano F., Paciolla I., Pagliuca M., Parola S., Pepe S., Petrillo A., Piantedosi F., Piccin L., Picozzi F., Pietroluongo E., Pignata S., Prati V., Riccio V., Rosanova M., Rossi A., Russo A., Salati M., Santabarbara G., Sbrana A., Simeone E., Silvestri A., Spada M., Tarantino P., Taveggia P., Tomei F., Vincenzo T., Trapani D., Trojanello C., Vanella V., Vari S., Ventriglia J., Vitale M. G., Vitiello F., Vivaldi C., Von Arx C., Zacchi F., Zampiva I., Zivi A., Daniele B., Ascierto P. A.
المساهمون: Ottaviano, M., Curvietto, M., Rescigno, P., Tortora, M., Palmieri, G., Giannarelli, D., Aieta, M., Assalone, P., Attademo, L., Avallone, A., Bloise, F., Bosso, D., Borzillo, V., Buono, G., Calderoni, G., Caputo, F., Carteni, G., Cavallero, D., Cavo, A., Ciardiello, F., Conca, R., Conteduca, V., De Falco, S., De Felice, M., De Laurentiis, M., De Placido, P., De Placido, S., De Santo, I., De Stefano, A., Della Corte, C. M., Di Franco, R., Di Lauro, V., Fabbrocini, A., Federico, P., Festino, L., Giordano, P., Giuliano, M., Gridelli, C., Grimaldi, A. M., Lia, M., Marretta, A. L., Massa, V., Mennitto, A., Merler, S., Merz, V., Messina, C., Messina, M., Milano, M., Minisini, A. M., Montesarchio, V., Morabito, A., Morgillo, F., Mucci, B., Nappi, L., Napolitano, F., Paciolla, I., Pagliuca, M., Parola, S., Pepe, S., Petrillo, A., Piantedosi, F., Piccin, L., Picozzi, F., Pietroluongo, E., Pignata, S., Prati, V., Riccio, V., Rosanova, M., Rossi, A., Russo, A., Salati, M., Santabarbara, G., Sbrana, A., Simeone, E., Silvestri, A., Spada, M., Tarantino, P., Taveggia, P., Tomei, F., Vincenzo, T., Trapani, D., Trojanello, C., Vanella, V., Vari, S., Ventriglia, J., Vitale, M. G., Vitiello, F., Vivaldi, C., Von Arx, C., Zacchi, F., Zampiva, I., Zivi, A., Daniele, B., Ascierto, P. A.
مصطلحات موضوعية: antineoplastic protocol, healthcare economics and organization, immunotherapy, lung neoplasm, melanoma, Adult, Antineoplastic Agents, Immunological, B7-H1 Antigen, Betacoronaviru, COVID-19, CTLA-4 Antigen, Coronavirus Infection, Drug Prescription, Female, Geography, Human, Infection Control, Italy, Male, Medical Oncology, Neoplasm, Oncologist, Pandemic, Pneumonia, Viral, Practice Patterns, Physicians', Prevalence, Programmed Cell Death 1 Receptor
الوصف: Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. Methods This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ 2 test for trends relative to the questions with 3 or more options. Results This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. Conclusion Our study highlights the efforts of Italian oncologists to maintain high standards of care ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33060148; info:eu-repo/semantics/altIdentifier/wos/WOS:000583157800005; volume:8; firstpage:e001154; lastpage:e001154; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; http://hdl.handle.net/11386/4756291Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85093476336
-
4
المؤلفون: Amalia Luce, Franco Morelli, Martina Viggiani, Vincenzo Caputo, Gaetano Facchini, Mario Giuliano, Ferdinando Costabile, Sabino De Placido, Michele Caraglia, Nicola Longo, Alessandro Palmieri, Simona Iaccarino, Carlo Buonerba, Erica Pietroluongo, Giuseppe Celentano, Marianna Abate, Matteo Ferro, Antonio Verde, Luca Scafuri, Antonella Lucia Marretta, Silvia Zappavigna, Livia Onofrio, Dario Ribera, Rocco Morra, Giuseppe Di Lorenzo, Pietro De Placido, Dario Bruzzese, Felice Crocetto, Zahrasadat Navaeiseddighi
المساهمون: Di Lorenzo, G., Zappavigna, S., Crocetto, F., Giuliano, M., Ribera, D., Morra, R., Scafuri, L., Verde, A., Bruzzese, D., Iaccarino, S., Costabile, F., Onofrio, L., Viggiani, M., Palmieri, A., De Placido, P., Marretta, A. L., Pietroluongo, E., Luce, A., Abate, M., Navaeiseddighi, Z., Caputo, V. F., Celentano, G., Longo, N., Ferro, M., Morelli, F., Facchini, G., Caraglia, M., De Placido, S., Buonerba, C., Lorenzo, G. D.
مصطلحات موضوعية: Oncology, Male, medicine.medical_specialty, Urology, 030232 urology & nephrology, 03 medical and health sciences, Prostate cancer, chemistry.chemical_compound, 0302 clinical medicine, Circulating tumor cell, Benzamide, Interquartile range, Internal medicine, Nitriles, Phenylthiohydantoin, medicine, Biomarkers, Tumor, PTEN, Enzalutamide, Humans, Protein Isoforms, Prospective Studies, Liquid biopsy, Prospective cohort study, Abiraterone, LHRH agonist, biology, business.industry, PTEN Phosphohydrolase, Protein Isoform, medicine.disease, Flow Cytometry, Neoplastic Cells, Circulating, Prospective Studie, Prostatic Neoplasms, Castration-Resistant, chemistry, Receptors, Androgen, 030220 oncology & carcinogenesis, Benzamides, biology.protein, Hormonal therapy, MDV3100, business, Nitrile, Human
الوصف: Introduction. Metastatic castration-resistant prostate cancer (mCRPC) is a deadly disease. Enzalutamide is an oral second-generation anti-androgen that is active in mCRPC. Circulating tumor cells (CTC) count correlates with overall survival (OS) in mCRPC, whereas detection of the androgen-receptor splice variant 7 (AR-V7) in CTC predicts poor response to oral second-generation anti-androgens. Also, loss of PTEN (phosphatase and tensin homolog) in CTC is a biomarker of poor prognosis in mCRPC. Patients and methods. In this translational study, we employed flow cytometry to assess total, PTEN–, and AR-V7+ CTC count per 7.5 mL of whole blood in a prospective cohort of patients with mCRPC receiving enzalutamide. Results. CTCs were assessed in a total of 45 men with mCRPC at baseline and at 12 weeks. Overall, CTC, PTEN– CTC, and AR-V7+ CTC detection rate was high, at baseline, with 84.4%, 71.1%, and 51.1% of samples showing at least 1 cell/7.5-mL blood, respectively, and after 3 months, with 93.3%, 64.4%, and 77.7% of samples showing at least 1 cell/7.5-mL blood, respectively. Median radiographic progression-free survival (rPFS) and OS were 6 (95% confidence interval [CI], 5.6-9) and 14.3 (95% CI, 12.8-20.3) months, respectively. Median (interquartile range) total CTC count at baseline was 5 (3; 8), whereas median (interquartile range) PTEN– CTC count was 2 (0; 4) and median (interquartile range) AR-V7+ CTC count was 1 (0; 3). At baseline, ≥ 5 versus < 5 total CTC count was associated with worse rPFS (hazard ratio [HR], 2.35; 95% CI, 1.14-4.84; P=.021) and OS (HR, 3.08; 95% CI, 1.45-6.54; P =.003), whereas ≥ 2 versus < 2 PTEN– CTC count was associated with worse rPFS (HR, 3.96; 95% CI, 1.8-8.72; P=.001) and OS (HR, 2.36; 95% CI, 1.12-5; P=.025). Finally, ≥ 1 versus < 1 AR-V7+ CTC count was also associated with worse rPFS (HR, 5.05; 95% CI, 2.4-10.64; P
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f80f190f158ce0c502783b3691b43a2cTest
http://hdl.handle.net/11591/463917Test -
5
المؤلفون: Sara Parola, Diletta Cavallero, Pietro De Placido, Rossella Di Franco, Francesca Zacchi, Giacomo Cartenì, Sabino De Placido, Claudia von Arx, Alice Rossi, Fernanda Picozzi, Pasquale Rescigno, Laura Attademo, Giovannella Palmieri, Carminia Maria Della Corte, Fabiana Vitiello, Anna Russo, Lucia Nappi, Michele Aieta, Alessia Mennitto, Fabiana Napolitano, Marco Messina, Giuseppe Buono, Valeria Merz, Marco De Felice, Stefano De Falco, Immacolata Paciolla, Irene De Santo, Dario Trapani, Antonio M. Grimaldi, Paolo Tarantino, Alessandro Morabito, Tortora Vincenzo, Stefano Pepe, Giuseppe Palmieri, Antonietta Fabbrocini, Diana Giannarelli, Alfonso De Stefano, Sabrina Vari, Cesare Gridelli, Vittorio Riccio, Angelica Petrillo, Martina Pagliuca, Giuseppe Calderoni, Margaret Ottaviano, Vincenza Conteduca, Michela Lia, Giuseppe Santabarbara, Ester Simeone, Valentina Borzillo, Francesca Caputo, Mario Rosanova, Marcello Curvietto, Pasquale Assalone, Brigitta Mucci, Raffaele Conca, Vito Vanella, Francovito Piantedosi, Vincenzo Montesarchio, Erica Pietroluongo, Lucia Festino, Federica Tomei, Vincenzo Di Lauro, Bruno Daniele, Caterina Vivaldi, Andrea Zivi, Veronica Prati, Pasqualina Giordano, Luisa Piccin, Francesco Bloise, Massimiliano Spada, Jole Ventriglia, Davide Bosso, Alessandro Marco Minisini, Massimiliano Salati, Monica Milano, Carlo Messina, Valentina Massa, Mario Giuliano, Claudia Trojanello, Antonella Lucia Marretta, Fortunato Ciardiello, Antonio Avallone, Marianna Tortora, Ilaria Zampiva, Alessia Cavo, Floriana Morgillo, Andrea Sbrana, Piera Federico, Maria Grazia Vitale, Sandro Pignata, Antonia Silvestri, Paola Taveggia, Sara Merler, Paolo A. Ascierto, Michelino De Laurentiis
المساهمون: Ottaviano, Margaret, Curvietto, Marcello, Rescigno, Pasquale, Tortora, Marianna, Palmieri, Giovannella, Giannarelli, Diana, Aieta, Michele, Assalone, Pasquale, Attademo, Laura, Avallone, Antonio, Bloise, Francesco, Bosso, Davide, Borzillo, Valentina, Buono, Giuseppe, Calderoni, Giuseppe, Caputo, Francesca, Cartenì, Giacomo, Cavallero, Diletta, Cavo, Alessia, Ciardiello, Fortunato, Conca, Raffaele, Conteduca, Vincenza, De Falco, Stefano, De Felice, Marco, De Laurentiis, Michelino, De Placido, Pietro, De Placido, Sabino, De Santo, Irene, De Stefano, Alfonso, Della Corte, Carminia Maria, Di Franco, Rossella, Di Lauro, Vincenzo, Fabbrocini, Antonietta, Federico, Piera, Festino, Lucia, Giordano, Pasqualina, Giuliano, Mario, Gridelli, Cesare, Grimaldi, Antonio Maria, Lia, Michela, Marretta, Antonella Lucia, Massa, Valentina, Mennitto, Alessia, Merler, Sara, Merz, Valeria, Messina, Carlo, Messina, Marco, Milano, Monica, Minisini, Alessandro Marco, Montesarchio, Vincenzo, Morabito, Alessandro, Morgillo, Floriana, Mucci, Brigitta, Nappi, Lucia, Napolitano, Fabiana, Paciolla, Immacolata, Pagliuca, Martina, Palmieri, Giuseppe, Parola, Sara, Pepe, Stefano, Petrillo, Angelica, Piantedosi, Francovito, Piccin, Luisa, Picozzi, Fernanda, Pietroluongo, Erica, Pignata, Sandro, Prati, Veronica, Riccio, Vittorio, Rosanova, Mario, Rossi, Alice, Russo, Anna, Salati, Massimiliano, Santabarbara, Giuseppe, Sbrana, Andrea, Simeone, Ester, Silvestri, Antonia, Spada, Massimiliano, Tarantino, Paolo, Taveggia, Paola, Tomei, Federica, Vincenzo, Tortora, Trapani, Dario, Trojanello, Claudia, Vanella, Vito, Vari, Sabrina, Ventriglia, Jole, Vitale, Maria Grazia, Vitiello, Fabiana, Vivaldi, Caterina, von Arx, Claudia, Zacchi, Francesca, Zampiva, Ilaria, Zivi, Andrea, Daniele, Bruno, Ascierto, Paolo Antonio, Ottaviano, M., Curvietto, M., Rescigno, P., Tortora, M., Palmieri, G., Giannarelli, D., Aieta, M., Assalone, P., Attademo, L., Avallone, A., Bloise, F., Bosso, D., Borzillo, V., Buono, G., Calderoni, G., Caputo, F., Carteni, G., Cavallero, D., Cavo, A., Ciardiello, F., Conca, R., Conteduca, V., De Falco, S., De Felice, M., De Laurentiis, M., De Placido, P., De Placido, S., De Santo, I., De Stefano, A., Della Corte, C. M., Di Franco, R., Di Lauro, V., Fabbrocini, A., Federico, P., Festino, L., Giordano, P., Giuliano, M., Gridelli, C., Grimaldi, A. M., Lia, M., Marretta, A. L., Massa, V., Mennitto, A., Merler, S., Merz, V., Messina, C., Messina, M., Milano, M., Minisini, A. M., Montesarchio, V., Morabito, A., Morgillo, F., Mucci, B., Nappi, L., Napolitano, F., Paciolla, I., Pagliuca, M., Parola, S., Pepe, S., Petrillo, A., Piantedosi, F., Piccin, L., Picozzi, F., Pietroluongo, E., Pignata, S., Prati, V., Riccio, V., Rosanova, M., Rossi, A., Russo, A., Salati, M., Santabarbara, G., Sbrana, A., Simeone, E., Silvestri, A., Spada, M., Tarantino, P., Taveggia, P., Tomei, F., Vincenzo, T., Trapani, D., Trojanello, C., Vanella, V., Vari, S., Ventriglia, J., Vitale, M. G., Vitiello, F., Vivaldi, C., Von Arx, C., Zacchi, F., Zampiva, I., Zivi, A., Daniele, B., Ascierto, P. A.
المصدر: Journal for ImmunoTherapy of Cancer
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)مصطلحات موضوعية: Male, Cancer Research, Immune checkpoint inhibitors, Programmed Cell Death 1 Receptor, Practice Patterns, Medical Oncology, B7-H1 Antigen, Antineoplastic Agents, Immunological, 0302 clinical medicine, Drug Prescription, Neoplasms, Surveys and Questionnaires, Pandemic, Prevalence, Surveys and Questionnaire, Infection control, Immunology and Allergy, CTLA-4 Antigen, 030212 general & internal medicine, Viral, Practice Patterns, Physicians', RC254-282, Clinical/Translational Cancer Immunotherapy, Oncologists, Geography, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, antineoplastic protocols, Immunological, Oncology, Italy, 030220 oncology & carcinogenesis, Molecular Medicine, Female, immunotherapy, Coronavirus Infections, Human, healthcare economics and organizations, Adult, Telemedicine, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Immunology, Antineoplastic Agents, lung neoplasms, Drug Prescriptions, Time-to-Treatment, 03 medical and health sciences, Betacoronavirus, medicine, melanoma, COVID-19, Humans, Infection Control, Pandemics, SARS-CoV-2, Medical prescription, Pharmacology, Physicians', Betacoronaviru, Coronavirus Infection, Cancer, Outbreak, Pneumonia, medicine.disease, lung neoplasm, antineoplastic protocol, Family medicine, healthcare economics and organization, Oncologist, Neoplasm
الوصف: BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region.MethodsThis survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2–positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher’s exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options.ResultsThis is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2–positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients’ planned treatment approach). The results from responders in Campania did not differ significantly from the national ones.ConclusionOur study highlights the efforts of Italian oncologists to maintain high standards of care for CPs treated with ICIs, regardless the regional prevalence of COVID-19, suggesting the adoption of similar solutions. Research on patients treated with ICIs and experiencing COVID-19 will clarify the safety profile to continue the treatments, thus informing on the most appropriate clinical conducts.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bbec51cbd465b3f335830ebbeec5befTest
http://hdl.handle.net/11568/1114478Test